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Background: Multiple solutes are retained in uremia, but it is currently unclear which solutes are toxic. Small
studies suggest that protein-bound solutes, such as p-cresol sulfate and indoxyl sulfate and intracellular solutes,
such as methylamine (MMA) and dimethylamine (DMA), may be toxic. Our objective was to test whether elevated
levels of these solutes were associated with mortality.
Methods: We conducted a prospective cohort study in 521 U.S. incident hemodialysis patients to evaluate
associations between these solutes and all-cause and cardiovascular mortality. P-cresol sulfate, indoxyl sulfate, MMA
and DMA levels were measured from frozen plasma samples obtained 2 to 6 months after initiation of dialysis.
Mortality data was available through 2004 using the National Death Index.
Results: Elevated (greater than the population median) p-cresol sulfate, MMA or DMA levels were not associated
with all-cause or cardiovascular mortality. Elevated indoxyl sulfate levels were associated with all-cause mortality but
not cardiovascular mortality (hazard ratio 1.30 (95% confidence interval 1.01, 1.69) p-value 0.043).
Conclusions: In this cohort of 521 incident hemodialysis patients, only elevated indoxyl sulfate levels were
associated with all-cause mortality. Further research is needed to identify causes of the toxicity of uremia to provide
better care for patients with kidney disease.
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SolutesBackground
There are currently nearly 400,000 patients with end-
stage renal disease (ESRD) living on dialysis in the US
[1]. These patients experience a high degree of morbidity
and mortality, with a first-year mortality rate of almost
20% [1]. More than 50% of the deaths of hemodialysis
patients in the US are attributed to cardiovascular disease* Correspondence: michal.melamed@einstein.yu.edu
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reproduction in any medium, provided the or[2], but both cardiovascular and non-cardiovascular death
risks are elevated relative to the general population [3].
Current guidelines for dialysis adequacy are based on the
removal of urea, a substance that is elevated in ESRD but
has not been shown to be toxic when it accumulates in an-
imals. In addition to urea, there are over 200 other solutes
with different characteristics that are retained in ESRD
patients treated with hemodialysis [4,5]. Some of these
potential putative toxins include the protein-bound solutes
p-cresol sulfate and indoxyl sulfate and intracellularly
sequestered methylamine (MMA) and dimethylamineral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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hemodialysis techniques [6,7].
Studies have shown p-cresol sulfate and indoxyl sulfate
to be associated with all-cause mortality, cardiovascular
events and endothelial dysfunction in patients with kid-
ney disease [8-12]. Epidemiological studies of MMA and
DMA have been fewer, but mouse studies demonstrated
that these compounds may be anorectic agents [13-15].
Due to the smaller nature of previous investigations and
varying dialysis practices in Europe, we tested the associ-
ations between these retained organic solutes and car-
diovascular and all-cause mortality in a relatively large,
well-characterized cohort of US hemodialysis patients.
Methods
Study population
Our study population was a sub-cohort of the CHOICE
Study. CHOICE was a national, prospective cohort study
investigating dialysis treatment choices and patient out-
comes in incident end-stage renal disease (ESRD) pa-
tients. A total of 1041 dialysis patients (767 hemodialysis
and 274 peritoneal dialysis) were enrolled in the USA
from 81 dialysis clinics in 19 states between October
1995 and June 1998. These included clinics associated
with Dialysis Clinic, Inc. (DCI, Nashville, TN; n = 923),
New Haven CAPD (New Haven, CT; n = 86) and St.
Raphael’s Hospital (New Haven, CT; n = 32). Entry cri-
teria included the initiation of chronic outpatient dialysis
in the preceding 3 months, ability to provide informed
consent for participation, age older than 17 years, and
ability to speak English or Spanish.
A specimen bank was established to store blood sam-
ples only from the DCI participants, and specimens were
obtained for 898 (97.3%) of the DCI enrollees. The Johns
Hopkins University School of Medicine Institutional Re-
view Board (IRB) and the review boards for the clinical
centers approved the study protocol. The Albert Einstein
College of Medicine, Stanford University, Johns Hopkins
University School of Medicine and the University of
California at San Francisco IRBs all approved the proto-
col detailed in this analysis. All patients gave written in-
formed consent before participation in the study. For
the current study, we restricted analysis to hemodialysis
patients.
Data collection
Plasma from special draws was available for 585 patients
(81% of all specimen bank participants treated with
hemodialysis) from 2 to 33 months after dialysis initi-
ation, with 521 patients having a sufficient volume (at
least 1 ml) of plasma within 6 months of dialysis initi-
ation. We measured uremic solutes in stored plasma
from these 521 CHOICE participants with available spe-
cial draw samples within 6 months of dialysis initiation.Detailed methods for the CHOICE special blood draw
have been previously described [16]. Briefly, a lavender-
top tube (EDTA) was collected pre-dialysis between 1996
and 1998, immediately centrifuged at 2500–3000 rpm for
15 minutes, separated and refrigerated in the dialysis unit
then shipped on ice and stored at −80° Celsius at the DCI
central laboratory (Nashville, TN). Specimens for this
study were thawed and divided into two equal aliquots at
the central laboratory, mailed by overnight courier on dry
ice to the two study laboratories (Stanford University
and the Albert Einstein College of Medicine), and then
stored at −80° Celsius at the respective laboratories until
they were thawed for analysis. Measurement of p-cresol
sulfate and indoxyl sulfate was performed at Stanford
University and methylamine and dimethylamine at the
Albert Einstein College of Medicine.Measurement of solutes
P-cresol sulfate (Figure 1) was assayed by HPLC as
previously described with fluorescence detection at ex-
citation 214 nm and emission 306 nm [17]. Recovery
of p-cresol sulfate with the assay was 100 ± 1% of
p-cresol sulfate added to normal plasma to achieve
concentrations similar to those found in patients on
dialysis (n = 4), and repeat p-cresol sulfate assay of
plasma from dialysis patients after freeze-thaw yielded
94 ± 7% of the original value (n = 6). Coefficient of vari-
ation was 0.51%.
Indoxyl sulfate (Figure 1) was measured as previously
described [17] on the same column as p-cresol sulfate
with fluorescence detection using excitation 295 nm and
emission 390 nm. Recovery with the assay was 100 ± 1
percent of indoxyl sulfate added to normal plasma to
achieve concentrations similar to those found in patients
on dialysis (n = 4) and repeat assay of after freeze-thaw
yielded 97 ± 10 percent of the original value (n = 6). Co-
efficient of variation was 0.60%.
MMA and DMA (Figure 1) levels were measured by
chromatography using a Shimadzu Prominence HPLC
system that consisted of two LC-20 AD pumps, a
DGU-20A3 degasser, a SIL-20A auto sampler, and an
RF-10AXL fluorescence detector. Determinations were
duplicated. Peak area was used for quantification [18].
Coefficients of variation were 0.44% for MMA and
0.24% for DMA.Outcomes
All-cause mortality
Mortality was ascertained primarily through linked Na-
tional Death Index (NDI) data, in addition to communi-
cation with the dialysis clinics, monthly reports from the
central DCI database, and linked Centers for Medicare
and Medicaid Services (CMS) data.
Solutes Characteristics Source
p-Cresol sulfate Protein bound Protein via gut bacteria
Indoxyl sulfate Protein bound Protein via gut bacteria
Monomethyl amine Intracellular 
sequestration
Choline breakdown

















Figure 1 Organic solutes and their characteristics and sources.
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Atherosclerotic cardiovascular disease (ASCVD) was
assigned as the cause of death in CHOICE through two
sources of information: adjudicated death records and
National Death Index (NDI) records. For adjudicated
death records, medical charts were reviewed by a Cardio-
vascular Disease Endpoints committee of trained physi-
cians using uniformly applied criteria modified from the
Cardiovascular Health Study [19] and the HEMO study
[20]. Each chart was independently reviewed by two
members of the committee and final immediate and
underlying causes of death were verified by an inde-
pendent adjudicator. Adjudicated causes of death were
determined to be ASCVD if either the immediate or
underlying cause of death was related to ischemic heart
disease, cerebrovascular disease, or peripheral vascular
disease, including abdominal aortic aneurysm and ische-
mic bowel disease.NDI records were obtained through 2004 for CHOICE
patients. These records provided cause of death informa-
tion (ICD-9/ICD-10 codes) from the U.S. Standard Certifi-
cate of Death. All codes in Section 27, Part I (including
immediate and underlying causes of death) were included,
whereas codes in Part II (contributing causes) were not.
Any code for coronary artery disease [ICD-9: 410, 411,
414.0, 414.8, 414.9, 429.2; ICD-10: I21, I22, I24, I25.0,
I25.1, I25.5, I25.6, I25.8, I25.9, I51.6], cerebrovascular dis-
ease [ICD-9: 431, 432.9, 433, 434, 436, 437.0, 437.1, 437.8,
437.9; ICD-10: I61, I62.9, I63, I64, I67.2, I67.9], abdominal
aortic aneurysm [ICD-9: 441; ICD-10, I71], peripheral vas-
cular disease [ICD-9: 443.9, 785.4; ICD-10: I73.9, R02], or
ischemic bowel [ICD-9: 557; ICD-10: K55] was considered
to be ASCVD-related.
ASCVD death was assigned in CHOICE if either the
adjudicated death record or NDI records indicated that
cause of death was ASCVD-related.
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Data regarding patient demographics and medical his-
tory were collected from a self-report questionnaire and
chart review. Race was self-categorized and coded as
African-American or white/other (including Hispanic,
Asian and Native American). The degree of comorbidity
severity was assessed using the Index of Coexistent
Disease (ICED), an instrument that has been validated in
dialysis populations [21]. The composite ICED score
ranged from 0 to 3 (with 3 indicating highest severity) and
was calculated from two constituent indices, the 19-axis
Index of Disease Severity (IDS) and the 11-axis Index of
Physical Impairment (IPI). Gastrointestinal disease in-
cluded a history of or active esophagitis, gastritis, ulcers,
pancreatitis, colitis, hiatal hernia, diabetic gastroparesis,
reflux, diverticulosis, polyps, hemorrhage or perforation.
Residual renal function was obtained from the baseline
self-report questionnaire and was defined as the ability to
produce at least 250 mL of urine daily. Albumin and cre-
atinine were measured as part of routine labs and values
in the 3-month window surrounding baseline were aver-
aged. High-sensitivity C-reactive protein (hs-CRP) levels
were measured in all patients with frozen serum available
in the CHOICE specimen bank a median 5 months from
dialysis initiation [16].
Statistical analysis
We first compared patient characteristics by levels of
retained solutes (divided at the median for each solute)
using Pearson’s χ2 tests for categorical variables and
ANOVA for continuous variables. In order to try to get
a better estimate of total solute burden, we created a
score for the number of solutes above the median for
each patient. The score ranged from 0, if all solutes were
below the median value, to 4, if all solute levels were
above the median value. Pearson’s correlations were
performed to evaluate correlations between solute levels
and serum creatinine levels.
We used Cox proportional hazards analysis to assess
the presence, strength, independence and statistical sig-
nificance of the association between individual solute
levels above vs. below the median value and cardiovascu-
lar and all-cause mortality. Modeling building included
potential confounders that were associated with the pre-
dictors and/or outcomes in univariate models. Potential
confounders included in the model were age at enroll-
ment, sex, race/ethnicity, comorbidity score (ICED), and
baseline albumin. Another model adjusted for all of the
above with the addition of obesity and baseline serum
creatinine values. Models were also stratified by potential
effect modifiers such as diabetes, albumin, and gastro-
intestinal disease. Gastrointestinal disease was considered
because p-cresol sulfate and indoxyl sulfate are produced
by gut bacteria. Patients were censored at transplantationor last date of follow-up (December 31, 2004). Sensitivity
analyses were performed with all-cause mortality updated
to 12/31/2008. All analyses were stratified by clinic to
account for possible inter-clinic variability. The thresh-
old for statistical significance was set at a two-sided
p-value of < 0.05. Statistical analyses were performed
using Stata software, version 11.2 (Stata Corporation,
College Station, TX).Results
Characteristics of the study population and retained
solute levels
Overall there were 521 participants with available plasma
for analysis. Their mean age was 58.3 years, 61% were
white, 54% were male and 39% had residual urine output
(defined as >250 ml/day) after one year of dialysis
(Table 1). Choices for Healthy Outcomes in Caring for
End-Stage Renal Disease (CHOICE) hemodialysis patients
who were excluded due to measurement >6 months after
start of dialysis or insufficient or missing plasma did not
differ from the study population, except for being slightly
older (61.5 vs. 58.3 years, P = 0.005) and sicker (36.9% vs.
29.3% with severe comorbidity, P = 0.04). The distribu-
tions of the solutes are shown in Figure 2. Higher p-cresol
sulfate (Table 1) levels were associated with older age,
male sex, lower BMI, higher mean albumin and lower
median CRP levels. Higher indoxyl sulfate levels were
associated with lower ICED scores and higher mean
serum albumin and creatinine levels. Higher MMA
levels were associated with older age, higher mean
serum albumin and creatinine. Higher DMA levels were
associated with a higher mean serum creatinine. Levels
of solutes were generally positively but weakly corre-
lated with levels of serum creatinine and each other
(Table 2).Associations between retained solute levels and all-cause
mortality
Three hundred thirty-three individuals died over the
course of the study. There were no statistically signifi-
cant associations between elevated solute levels and all-
cause mortality except for the hazard ratio for indoxyl
sulfate in the fully-adjusted model (hazard ratio (HR)
1.30 (95% confidence intervals (CI): 1.01, 1.69) (Table 3).
The number of solutes with values above the median
was not associated with all-cause mortality. The lack of
association did not change when stratifying the popula-
tion by baseline albumin, creatinine or the presence of
gastrointestinal disease (data not shown). Additionally,
the extension of all-cause mortality data through 2008
did not change the associations between solute levels
and mortality (data not shown).
Table 1 Characteristics of study participants by levels of solutes





Low High Low High Low High Low High
0.0-3.l 3.1-11.1 0-1.6 1.6-6.8 24.2-49.6 49.7-190.6 7.6-18.3 18.3-33.9
N (%) 521 (100%) 261 (50.1) 260 (49.9) 261 (50.1) 260 (49.9) 262 (50.3) 259 (49.7) 263 (50.5) 258 (49.5)
Demographics
Mean age (SD) 58.3 (14.7) 56.6 (14.2)* 59.9 (14.9)* 57.3 (13.9) 59.2 (15.3) 56.9 (15.2)* 59.6 (14.0)* 58.6 (14.9) 57.9 (14.4)
% white 61.0 61.7 60.4 59.0 63.1 63.4 58.7 63.5 58.5
% male 54.1 47.1* 61.2* 54.4 53.9 50.0 58.3 53.6 54.7
Clinical
% ICED = 3 29.2 31.4 26.9 35.6* 22.7* 27.1 31.3 26.2 32.2
Mean BMI (SD) 27.4 (7.0) 28.3 (7.4)* 26.5 (6.5)* 27.7 (7.3) 27.1 (6.6) 27.5 (7.7) 27.3 (6.2) 27.1 (7.4) 27.8 (6.5)
% with residual urine output
at 1 year
38.9 41.4 36.6 42.9 35.2 37.4 40.4 42.3 35.6
Mean KtV (SD) 1.27 1.26 1.29 1.24* 1.31* 1.27 1.27 1.27 1.27
Cause of ESRD
Diabetes mellitus 47.8 50.2* 45.4* 56.7** 38.9** 49.2 46.3 46.4 49.2
Hypertension 18.2 13.0* 23.5* 14.9** 21.5** 16.0 20.5 19.4 17.1
Glomerulonephritis 16.1 18.4* 13.9* 10.3** 21.9** 14.5 17.8 15.2 17.1
Other 17.9 18.4* 17.3* 18.0** 17.7** 20.2 15.4 15.2 17.1
% with diabetes 54.9 56.7 53.1 63.2** 46.5** 55.7 54.1 53.6 56.2
% with hypertension 97.0 96.5 97.6 96.6 97.5 97.5 96.6 96.5 97.6
% with gastrointestinal disease 41.8 44.8 38.9 43.3 40.4 39.7 44.0 42.6 41.1
Laboratory
Mean albumin (SD) 3.6 (0.4) 3.6 (0.4)* 3.7 (0.3)* 3.6 (0.4)** 3.7 (0.3)** 3.6 (0.4)* 3.7 (0.3)* 3.7 (0.3) 3.6 (0.4)
Mean creatinine (SD) 7.3 (2.4) 7.1 (2.5) 7.5 (2.3) 6.5 (2.1)** 8.1 (2.5)** 6.9 (2.4)** 7.8 (2.4)** 6.9 (2.4)** 7.7 (2.4)**
Median CRP (IQR) 0.4 (0.2-1.1) 0.4 (0.2-1.5)* 0.4 (0.2-0.8)* 0.5 (0.2-1.2) 0.4 (0.2-1.0) 0.4 (0.2-1.2) 0.4 (0.2-1.0) 0.4 (0.2-1.3) 0.4 (0.2-1.0)
Low, below population median value for solute; high, at or above population median values for solute. Diabetes, hypertension, and gastrointestinal disease were
defined by domains of the index of disease severity scale of the ICED. n = 521 for all variables except BMI (n = 492), albumin (n = 515), creatinine (n = 516), CRP
(n = 517), Kt/V (n = 401) and residual urine output at 1 year (n = 447).
*P < 0.05 for high vs. low level of solute, by ANOVA or χ2 test.
**P < 0.001 for high vs. low level of solute, by ANOVA or χ2 test.
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cardiovascular mortality
There were no associations between elevated solute
levels and cardiovascular mortality in either unadjusted
or multivariable-adjusted models (Table 4). The un-
adjusted estimate for p-cresol sulfate was elevated HR
1.30 (95% CI: 0.89, 1.89) but did not reach statistical sig-
nificance. There was also no association in multivariable
adjusted models between cardiovascular mortality and
the number of solutes above the median. The lack of
association did not change when stratifying the popula-
tion by baseline albumin, creatinine or the presence of
gastrointestinal disease (data not shown).
Discussion
In this national cohort of incident hemodialysis patients
we found no associations between elevated plasma levelsof total p-cresol sulfate, MMA or DMA and all-cause or
cardiovascular mortality. We did find an elevated risk of
all-cause mortality with higher indoxyl sulfate levels but
only in the fully-adjusted model. While this finding is
similar to previous research detailed below, in the setting
of multiple comparisons in the current analysis and the
borderline p-value (0.043), we are cautious with the sig-
nificance of this finding. The search for uremic toxins
has been ongoing in the nephrology community for
many years [22]. The use of urea measurement alone is
a crude measure of uremia that does not reflect the
multitude of solutes that accumulate during renal failure
and contribute to disease. Discovery of toxic solutes that
accumulate in renal failure and could be diminished by
alterations in dialysis or by reduction in their production
would allow for tailoring of dialysis therapy and ultim-
ately improve patient outcomes. For example, protein-
A P-cresol sulfate B Indoxyl sulfate
Indoxyl sulfate, mg/dl
C Methylamine D Dimethylamine
Figure 2 Distribution of measured solutes. Solid lines, median values; dashed lines, interquartile range (IQR). A. P-cresol sulfate, B. Indoxyl
sulfate, C. Methylamine, D. Dimethylamine.
Table 2 Correlations between serum creatinine and retained solutes: p-cresol sulfate, indoxyl sulfate, methylamine and
dimethylamine
Solute Serum creatinine p-cresol sulfate Indoxyl sulfate Methylamine Dimethylamine
Serum creatinine 1.00
p-cresol sulfate 0.10 1.00
0.02
Indoxyl sulfate 0.41 0.33 1.00
< 0.001 < 0.001
Methylamine 0.17 0.12 0.18 1.00
< 0.001 0.009 < 0.001
Dimethylamine 0.16 0.10 0.19 0.13 1.00
< 0.001 0.02 < 0.001 0.002
Data presented by cell: upper part of cell: ρ, lower part of cell: p-value.
Melamed et al. BMC Nephrology 2013, 14:134 Page 6 of 10
http://www.biomedcentral.com/1471-2369/14/134
Table 3 Relative hazards (95% CI) for all-cause mortality by solute
Solute Overall (continuous,
per 1 SD)
Hazard ratio (95% CI)
Below median Above median
P-cresol sulfate
Range of values 0-11.1 mg/dl (SD = 1.76 mg/dl) 0-3.1 mg/dl 3.1-11.1 mg/dl
Unadjusted 1.05 (0.93-1.17) Reference 1.10 (0.88-1.37)
Adjusted* 1.02 (0.90-1.16) Reference 1.03 (0.81-1.31)
+ obesity, creatinine 1.02 (0.90-1.16) Reference 1.03 (0.83-1.28)
Indoxyl sulfate
Range of values 0-6.8 mg/dl (SD = 1.11 mg/dl) 0-1.6 mg/dl 1.6-6.8 mg/dl
Unadjusted 0.93 (0.84-1.04) Reference 1.03 (0.83-1.28)
Adjusted* 0.98 (0.87-1.10) Reference 1.14 (0.90-1.44)
+ obesity, creatinine 1.04 (0.91-1.18) Reference 1.30 (1.01-1.69)
MMA
Range of values 24.2-190.6 ug/L (SD = 16.48 ug/L) 24.2-49.6 ug/L 49.7-190.6 ug/L
Unadjusted 1.10 (0.99-1.23) Reference 1.01 (0.81-1.26)
Adjusted* 1.05 (0.94-1.17) Reference 0.94 (0.74-1.20)
+ obesity, creatinine 1.09 (0.97-1.22) Reference 1.00 (0.78-1.29)
DMA
Range of values 7.6-33.9 uM (SD = 3.69 uM) 7.6-18.3 uM 18.3-33.9 uM
Unadjusted 0.96 (0.86-1.07) Reference 0.86 (0.69-1.08)
Adjusted* 1.00 (0.89-1.12) Reference 0.88 (0.69-1.11)
+ obesity, creatinine 1.01 (0.90-1.14) Reference 0.91 (0.71-1.17)
Total Score (vs. 0)** Continuous 1 2 3 4
Unadjusted 1.00 (0.91-1.09) 1.53 (1.03-2.27) 1.24 (0.87-1.77) 1.21 (0.83-1.77) 1.14 (0.72-1.79)
Adjusted* 0.99 (0.89-1.10) 1.28 (0.85-1.94) 1.24 (0.85-1.80) 0.96 (0.64-1.43) 1.26 (0.78-2.04)
+ obesity, creatinine 1.04 (0.93-1.16) 1.29 (0.84-1.99) 1.28 (0.86-1.90) 1.06 (0.69-1.64) 1.49 (0.88-2.51)
All models stratified by clinic cluster. *Adjustment: basic model, age at enrollment, sex, race, comorbidity score (ICED), and baseline albumin: + obesity and
creatinine value. **Total number of solutes with levels above the population median.
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sulfate can be removed more effectively by increasing
dialyzer surface area and dialysate flow [23]. Similarly,
intracellularly sequestered compounds such as MMA
would be expected to be removed best by longer dialysis
sessions.
The solute p-cresol sulfate has had the most observa-
tional data to suggest toxicity. While our study showed a
borderline significant association between elevated p-
cresol sulfate and cardiovascular mortality, it disappeared
with adjustment for other factors including residual renal
function and baseline co-morbidities. In a cohort of 139
patients with different stages of CKD (ranging from stage
2 to stage 5 on dialysis), baseline free and total p-cresol
sulfate showed an inverse relationship with renal function
and a positive relationship with vascular calcification [10].
This study, which included only Caucasian prevalent CKD
patients, measured free and total p-cresol sulfate [10].
They also found that free but not total p-cresol sulfate
levels were associated with mortality [10]. This group,using the same Caucasian cohort, showed that elevated
levels of indoxyl sulfate were also associated with overall
and cardiovascular mortality [9]. Another study in 100
prevalent hemodialysis patients in Taiwan also showed an
association between free and total p-cresol with cardiovas-
cular events [8]. A study of 175 prevalent hemodialysis pa-
tients in Belgium showed an elevated risk of all-cause
mortality for patients with high free p-cresol sulfate levels
(HR 2.28; 95% CI: 1.12, 4.64) [24]. A later study from the
same group in Belgium showed that in 499 patients with
mild to moderate kidney disease, higher baseline free p-
cresol levels were associated with cardiovascular events
(HR 1.39, p = 0.04) [11]. Most of the previous studies were
limited by small sample sizes with few events and, thus,
an inability to fully adjust in statistical models. Ours is also
the only US based study evaluating these associations with
differing patient populations, medications, dialysis practice
patterns and lastly outcomes (CV mortality versus CV
events). These differences compared to previous studies
may partially explain the differential results.
Table 4 Relative hazards (95% CI) for cardiovascular mortality by solute
Solute Overall (continuous,
per 1 SD)
Hazard ratio (95% CI)
Below median Above median
P-cresol sulfate
Range of values 0-11.1 mg/dl (SD = 1.76 mg/dl) 0-3.1 mg/dl 3.1-11.1 mg/dl
Unadjusted 1.09 (0.93-1.28) Reference 1.35 (0.98-1.85)
Adjusted* 1.06 (0.89-1.27) Reference 1.24 (0.87-1.77)
+ obesity, creatinine 1.07 (0.88-1.29) Reference 1.30 (0.89-1.89)
Indoxyl sulfate
Range of values 0-6.8 mg/dl (SD = 1.11 mg/dl) 0-1.6 mg/dl 1.6-6.8 mg/dl
Unadjusted 0.87 (0.74-1.03) Reference 0.93 (0.67-1.27)
Adjusted* 0.88 (0.74-1.06) Reference 0.93 (0.66-1.31)
+ obesity, creatinine 0.96 (0.79-1.18) Reference 1.11 (0.76-1.64)
MMA
Range of values 24.2-190.6 ug/L (SD = 16.48 ug/L) 24.2-49.6 ug/L 49.7-190.6 ug/L
Unadjusted 1.06 (0.90-1.24) Reference 0.99 (0.72-1.36)
Adjusted* 0.97 (0.82-1.15) Reference 0.91 (0.64-1.29)
+ obesity, creatinine 1.06 (0.89-1.26) Reference 1.01 (0.69-1.48)
DMA
Range of values 7.6-33.9 uM (SD = 3.69 uM) 7.6-18.3 uM 18.3-33.9 uM
Unadjusted 0.97 (0.83-1.14) Reference 0.81 (0.58-1.13)
Adjusted* 1.00 (0.85-1.18) Reference 0.84 (0.59-1.18)
+ obesity, creatinine 1.02 (0.86-1.22) Reference 0.89 (0.61-1.29)
Total Score (vs. 0)** Continuous 1 2 3 4
Unadjusted 1.00 (0.88-1.14) 1.22 (0.70-2.13) 1.00 (0.61-1.65) 0.78 (0.45-1.35) 1.43 (0.79-2.59)
Adjusted* 0.97 (0.84-1.13) 1.03 (0.57-1.84) 0.89 (0.52-1.51) 0.59 (0.33-1.07) 1.37 (0.73-2.58)
+ obesity, creatinine 1.05 (0.89-1.25) 1.11 (0.60-2.06) 0.97 (0.55-1.71) 0.72 (0.38-1.37) 1.91 (0.94-3.88)
All models stratified by clinic cluster. *Adjustment: basic model, age at enrollment, sex, race, comorbidity score (ICED), and baseline albumin: + obesity and
creatinine value. **Total number of solutes with levels above the population median.
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of total levels of protein-bound solutes may not reflect
free levels due to variations in albumin concentration
and the extent of protein binding. Other studies have
shown that free but not total levels show stronger asso-
ciations with mortality [10]. However, stratification of
our results by albumin status did not show differential
effects. Our study also used specimens from 2 to
6 months after dialysis initiation. The ideal timing of
specimen collection for this type of study is unknown.
Collecting samples before the initiation of dialysis may
lead to more confounding by residual renal function,
whereas samples from later in the course of dialysis may
lead to survival bias, as not all the participants who
started on dialysis will have survived to specimen collec-
tion. The uremic toxins we studied are all poorly cleared
by current dialysis therapies and by the dialysis therapies
used at the initiation of the CHOICE study, therefore,
one would not expect large changes in levels after dialy-
sis initiation, but this has never been studied.Among patients receiving conventional dialysis, we
demonstrated that protein-bound uremic solutes were
not independently associated with mortality in a well-
dialyzed cohort. This finding was consistent among all
the uremic solutes and did not differ by diabetic or nu-
tritional status. Our finding are similar to other studies
evaluating associations between potential uremic toxins
and mortality which also had null results [25]. Recent
trials comparing more frequent or nocturnal daily dialy-
sis have shown considerable improvement in outcomes,
which has been attributed to improved dialysis and
clearance [26,27]. The quality indicators such as lower
blood pressure, hospitalization rates, and mortality, how-
ever, may all be related to improved volume, electrolytes
and blood pressure, rather than greater removal of
uremic solutes. This hypothesis still needs to be tested
in the recently completed trials with both cardiovascular
and mortality end-points.
We have focused only on major clinical events, mor-
tality and CVD mortality. However, other disabilities
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sis, such as neurocognitive and sleep disorders, quality
of life indicators, response to medication such as ESAs
and malnutrition that may benefit from increased solute
clearance but further work is needed to test the relation
of these non-urea solutes to such outcomes. Identification
of solutes or classes of solutes associated with mortality
and morbidiy could also lead to strategies for reducing
their production or enhancing their elimination.
There are several limitations to our study. The first is
that we did not have data on the entire CHOICE
hemodialysis cohort, which may have introduced an un-
measured selection bias, since only those who survived
and had the correct sample in the specimen bank were
included. Our final cohort had less severe comorbid ill-
ness and early mortality than the overall CHOICE sam-
ple, in part because some specimens were obtained later
in patients’ course of dialysis therapy. Another limitation
is the use of plasma from a single time point as the ex-
posure. Unfortunately, most studies of uremic solutes
have had this limitation. Finally, like all previous studies
on these potential uremic toxins, our study is observa-
tional and therefore causality cannot be directly inferred.
These limitations are balanced by the several strengths
of our study, including prospective design with inclusion
of only incident hemodialysis patients; detailed and pre-
cise information for demographic, clinical and treatment
factors; and systematic adjudication of baseline comor-
bid conditions as well as outcomes. These comprehen-
sive data allowed us to extensively adjust for potential
confounders in our analysis.
Conclusions
In summary, in this large national incident dialysis co-
hort, baseline levels of total p-cresol sulfate, MMA, and
DMA were not associated with all-cause or cardiovascu-
lar mortality. Elevated levels of indoxyl sulfate did show
an association with all-cause mortality but not cardio-
vascular mortality and not in all models. Studies in the
future should focus on longitudinal measurements and
on other putative uremic toxins, including asymmetric
dimethyl arginine (ADMA) and others. Further research
is warranted in this area in order to try to improve dialy-
sis patient outcomes.
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